

# A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin re-uptake inhibitors and lofepramine

<b>Submission date</b> 25/04/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 25/04/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 08/11/2022	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Christopher Thompson

### Contact details

Academic Psychiatry  
University of Southampton  
Royal South Hants Hospital  
Brinton's Terrace  
Southampton  
United Kingdom  
SO14 0YG  
+44 (0)23 80 825 533  
ct1@soton.ac.uk

## Additional identifiers

EudraCT/CTIS number

IRAS number

**ClinicalTrials.gov number**

**Secondary identifying numbers**

HTA 96/61/11

## **Study information**

### **Scientific Title**

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin re-uptake inhibitors and lofepramine

### **Acronym**

AHEAD

### **Study objectives**

This project will be a three-arm randomised controlled open label controlled study of the cost effectiveness of tricyclic antidepressants, SSRIs and lofepramine in the primary care setting. Outcome will be assessed over a one year period using well established clinical, quality of life, and economic measures at intervals of one or three months. The objectives are 1) to compare the cost effectiveness and cost utility of the initial choice of SSRIs and tricyclic antidepressants in general practice and 2) to compare the cost effectiveness and cost utility of the initial choice of SSRIs and lofepramine in general practice.

Please note that, as of 10 January 2008, the anticipated end date of this trial has been updated from 31 July 2002 to 31 July 2003.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Not provided at time of registration.

### **Study design**

Three-arm randomised controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Not specified

### **Study type(s)**

Treatment

### **Participant information sheet**

### **Health condition(s) or problem(s) studied**

Mental and behavioural disorders: Depression, anxiety, neuroses

### **Interventions**

Tricyclic antidepressants, selective serotonin re-uptake inhibitors and lofepramine

### **Intervention Type**

Drug

### **Phase**

Not Specified

### **Drug/device/biological/vaccine name(s)**

tricyclic antidepressants, SSRIs and lofepramine

### **Primary outcome measure**

Quality of life and economic measures.

Clinical outcomes are being assessed through use of the Clinical Interview Schedule, Revised version; the Hospital Anxiety and Depression Scale; the Euroqol; and the SF-36 Quality of Life Scale. Use of health services is being assessed through patient-completed questionnaires, and through detailed examination of general practice medical records.

### **Secondary outcome measures**

Not provided at time of registration.

### **Overall study start date**

01/02/1999

### **Completion date**

31/07/2003

## **Eligibility**

### **Key inclusion criteria**

The sample group is of 327 patients who are prescribed antidepressant drugs by their general practitioner. The sociodemographic characteristics and other features of this group will be analysed, to evaluate whether the sample is representative of the wider population of general practice patients received antidepressant treatment.

### **Participant type(s)**

Patient

### **Age group**

Not Specified

### **Sex**

Both

### **Target number of participants**

327

**Key exclusion criteria**

Not provided at time of registration.

**Date of first enrolment**

01/02/1999

**Date of final enrolment**

31/07/2003

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Academic Psychiatry**

Southampton

United Kingdom

SO14 0YG

## **Sponsor information**

**Organisation**

Department of Health (UK)

**Sponsor details**

Quarry House

Quarry Hill

Leeds

United Kingdom

LS2 7UE

+44 (0)1132 545 843

Sheila.Greener@doh.gsi.gov.uk

**Sponsor type**

Government

**Website**

<http://www.dh.gov.uk/en/index.htm>

**ROR**

<https://ror.org/03sbpja79>

# Funder(s)

## Funder type

Government

## Funder Name

NIHR Health Technology Assessment Programme - HTA (UK)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

Not provided at time of registration

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	HTA monograph	01/05/2005		Yes	No